Fenwick Represents BioAge Labs in $115M Upsized Public Offering

Fenwick represented BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, in its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 884,615 shares of common stock in connection with the offering. All of the shares of common stock are being offered by BioAge.

Goldman Sachs & Co. LLC, Piper Sandler and Citigroup are acting as joint book-running managers for the offering. More information can be obtained from the BioAge’s announcement.

The Fenwick transaction team included corporate partners Matt Rossiter, Rob Freedman and Julia Forbess and associates Adam Conway, Lindsey Macalalad Phillip Craig and Kennedii Brock.